Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 01, 2022 07:00 ET | Source: Akouos, Inc.

Akouos to Present at Cowen 42nd Annual Heath Care Conference

BOSTON, March 01, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with...
February 07, 2022 07:00 ET | Source: Akouos, Inc.

Akouos Presents Nonclinical Data Demonstrating Potential Applicability of Precision Genetic Medicine Platform for a Broad Range of Inner Ear Conditions at the Association for Research in Otolaryngology 45th Annual Mid-Winter Meeting

- Data from two nonclinical studies evaluating protein expression and tolerability support future clinical development of AK-antiVEGF for the treatment of vestibular schwannoma - AAVAnc80 and a...
January 31, 2022 07:00 ET | Source: Akouos, Inc.

Akouos to Participate in Upcoming February Virtual Investor Conferences

BOSTON, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with...
January 07, 2022 07:00 ET | Source: Akouos, Inc.

Akouos to Present at the Association for Research in Otolaryngology 45th Annual Mid-Winter Meeting

BOSTON, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling...
November 22, 2021 07:00 ET | Source: Akouos, Inc.

Akouos to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference

BOSTON, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with...
November 12, 2021 07:00 ET | Source: Akouos, Inc.

Akouos Reports Third Quarter 2021 Financial Results and Provides Business Highlights

- Continued progress toward planned IND submissions for AK-OTOF in the first half of 2022 and AK-antiVEGF in 2022 - Expanded leadership team with appointment of Stacy Price as chief technical officer...
November 01, 2021 07:00 ET | Source: Akouos, Inc.

Akouos Appoints Stacy Price as Chief Technical Officer

BOSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling...
October 20, 2021 07:00 ET | Source: Akouos, Inc.

Akouos to Present at Jefferies Gene Therapy/Editing Summit

BOSTON, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with...
September 07, 2021 07:00 ET | Source: Akouos, Inc.

Akouos to Present at Upcoming September Virtual Investor Conferences

BOSTON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with...
August 12, 2021 07:00 ET | Source: Akouos, Inc.

Akouos Reports Second Quarter 2021 Financial Results and Provides Business Highlights

- Announced European Commission designation of AK-OTOF as an orphan drug for the treatment of otoferlin gene-mediated hearing loss - Advanced both AK-OTOF and AK-antiVEGF towards planned IND...